NatHER: protocol for systematic evaluation of trends in survival among patients with HER2-positive advanced breast cancer

BACKGROUND: Human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) is an aggressive form of breast cancer and is historically associated with poor outcomes compared with HER2-negative MBC. Since 1998, four drugs have been globally approved for the targeted treatment...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Syst Rev
Prif Awduron: Korner, Eli J., Morris, Anne, Allen, Isabel Elaine, Hurvitz, Sara, Beattie, Mary S., Kalesan, Bindu
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2015
Pynciau:
Protocol
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4591587/
https://ncbi.nlm.nih.gov/pubmed/26428301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13643-015-0118-z
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg